



11 November 2019

Dr. Kevin Smith  
President & CEO, University Health Network  
[kevin.smith@uhn.ca](mailto:kevin.smith@uhn.ca)

Dr. Brian D. Hodges  
EVP and Chief Medical Officer  
[brian.hodges@uhn.ca](mailto:brian.hodges@uhn.ca)

Dear Dr. Hodges and Smith:

Further to our letter of October 23, 2019 we write again in respect to the Baker-Odame Review ("Review of chelation therapy practice in the red cell disorders program at UHN") provided to us on 30 September 2019.

Among the other requests issued in our letter, we ask again that you provide at your earliest convenience all the rough and formal notes recorded by Drs. Odame and Baker, during the Review in all 71 patients exposed to deferiprone. These would include the names of all patients whose EMRs were examined.

We request a reply to this letter at your earliest convenience.

Sincerely yours,

A handwritten signature in black ink that reads "Brenda L. Gallie".

Brenda L. Gallie, MD, FRCSC, CM, OOnt  
Head, Retinoblastoma Programs,  
Hospital for Sick Children and Alberta Children's  
Hospital  
Associate Scientist, TECHNA Institute, UHN  
Professor, Ophthalmology, Medical Biophysics,  
Molecular Genetics, University of Toronto  
555 University Ave, Toronto M5G 1X8  
[brenda@gallie.ca](mailto:brenda@gallie.ca)

A handwritten signature in black ink that reads "Nancy F. Olivieri".

Nancy F. Olivieri, MD, MA, FRCPC  
Professor, Pediatrics, Medicine and Public Health  
Sciences,  
University of Toronto, Canada;  
Senior Scientist, Toronto General Hospital, UHN  
200 Elizabeth Street, EN 13-222,  
Toronto, Ontario Canada M5G 2C4  
[nancy@hemoglobal.org](mailto:nancy@hemoglobal.org)

Cc:

Dr. Michael Baker  
[michael.baker@uhn.ca](mailto:michael.baker@uhn.ca)